Article
Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Annals of surgical oncology - 1 Jul 2013
Duldulao Marjun P, Lee Wendy, Nelson Rebecca A, Li Wenyan, Chen Zhenbin, Kim Joseph, Garcia-Aguilar Julio
Abstract excerpt
BACKGROUND: Mutations in KRAS and TP53 are common in colorectal carcinogenesis and are associated with resistance to therapy. Rectal cancers carrying both mutations are less likely to respond to neoadjuvant chemoradiation therapy (CRT) compared with wild-type tumors. Codon-specific KRAS mutations are associated with variable resistance to targeted therapies, but their association with rectal cancer response to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.